Standard BioTools reports preliminary FY2024 revenue ~$174M; Q4 ~$46.5M

STANDARD BIOTOOLS INC.

2024-FY EPS reported -$0.52 revenue$174,432,000

Preliminary Q4 2024 revenue approximately $46.5 million.
Full year 2024 revenue approximately $174 million, at top end of revised guidance.
CEO cites industry-wide headwinds and progress reducing operating expenses via SBS.
Company to discuss 2025 outlook when reporting final Q4/FY results later in Q1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.